## Amendments to the Claims

Please amend Claim 2. Please add Claims 11-13. Upon entry of the Amendment, Claims 2, 3 and 8-13 are pending. The Claim Listing below will replace all prior versions of the claims in the application:

## **Claim Listing**

- 1. (Canceled)
- 2. (Currently Amended) A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer, said homopolymer characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent wherein the unit dosage form is a tablet.
- 3. (Previously presented) The pharmaceutical composition of Claim 2 wherein the polymer is crosslinked using epichlorohydrin.

## Claims 4-7. (Canceled)

8. (Previously Presented) A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer, said homopolymer characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent wherein the unit dosage form is a capsule.

- 9. (Previously Presented) The pharmaceutical composition of Claim 2, wherein the polydiallylamine homopolymer is in the free base form.
- 10. (Previously Presented) The pharmaceutical composition of Claim 2, wherein the polydiallylamine homopolymer is a salt or partial salt.
- 11. (New) The pharmaceutical composition of Claim 8, wherein the polydiallylamine homopolymer is in the free base form.
- 12. (New) The pharmaceutical composition of Claim 8, wherein the polydiallylamine homopolymer is a salt or partial salt.
- 13. (New) The pharmaceutical composition of Claim 8, wherein the polymer is crosslinked using epichlorohydrin.